Active Clinical Trials at
UCSF – Washington Cancer Center
A Randomized Phase III, Double-Blinded, Placebo-Controlled Trial of Aspirin
as Adjuvant Therapy for Node-Positive HER2- Negative Breast Cancer - The ABC Trial
This randomized phase III trial studies how well aspirin works in preventing
the cancer from coming back (recurrence) in patients with human epidermal
growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery,
and/or radiation therapy. Aspirin is a drug that reduces pain, fever,
inflammation, and blood clotting. It is also being studied in cancer prevention.
Giving aspirin may reduce the rate of cancer recurrence in patients with
For More information:
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475
as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=
1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant
This randomized Phase III trial is for patients who have been diagnosed
with “triple-negative” breast cancer. Triple negative means
that this type of cancer does not have receptors for estrogen, progesterone,
or the protein HER2 that may be found in other breast cancers. The patient
must have had preoperative chemotherapy that the breast cancer has at
least partially survived. The current standard of care may include no
more treatment after surgery or the doctor may recommend further chemotherapy
This study compares the usual approach (no treatment or additional treatment
as recommended by your doctor) and one year of the experimental drug MK-3475
(also called pembrolizumab). This study will allow researchers to know
whether treatment with MK-3475 is better, the same, or worse than the
usual approach alone.
For More Information: https://clinicaltrials.gov/ct2/show/NCT02954874?term=s1418&draw=2&rank=1
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/
Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic
This Phase III trial is for patients who have HER2-positive metastatic
breast cancer. The usual approach to this cancer is chemotherapy combined
with trastuzumab and pertuzumab. This trial compares the usual treatment
and placebo versus the usual treatment
and atezolizumab. Atezolizumab is already approved by the FDA for use in non-small cell
lung and urinary cancer. The use in this study is considered experimental.
This trial is double-blinded, meaning that neither the patient nor the
health care team will know which treatment you will be receiving.
For More Information: https://clinicaltrials.gov/ct2/show/NCT03199885?term=br004&draw=2&rank=2
Lung Cancer In Older Adults: Treatment Toxicity Through the Patient’s Lens
This study is for patients who are 65 years or older, have lung cancer
and will be starting a new treatment. The purpose of this study is to
learn more about how older adults tolerate lung cancer treatment and how
treatment affects their daily lives.
For More Information: http://cancer.ucsf.edu/support/older-adult/research
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies
in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
This screening study is for patients who have been diagnosed with non-small
cell lung cancer. The patient will be asked to submit their tumor sample
to test for specific genes and proteins. Based on the test results, the
patient may be assigned to a treatment substudy. This will take place
when the patient progresses.
For More Information: https://clinicaltrials.gov/ct2/show/NCT03851445?term=lungmap&draw=2&rank=1
GO: Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer
This purpose of this study is to investigate the alterations in the gut
microbiome that occur during the course of treatment for colorectal cancer (CRC).
For More Information: